PDS Biotechnology Corp
NASDAQ:PDSB
Balance Sheet
Balance Sheet Decomposition
PDS Biotechnology Corp
PDS Biotechnology Corp
Balance Sheet
PDS Biotechnology Corp
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
0
|
8
|
14
|
130
|
106
|
88
|
35
|
12
|
29
|
65
|
74
|
57
|
42
|
|
| Cash Equivalents |
0
|
8
|
14
|
130
|
106
|
88
|
35
|
12
|
29
|
65
|
74
|
57
|
42
|
|
| Total Receivables |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
2
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
3
|
2
|
3
|
|
| Total Current Assets |
0
|
9
|
15
|
131
|
107
|
89
|
36
|
15
|
30
|
67
|
77
|
59
|
45
|
|
| PP&E Net |
0
|
0
|
1
|
3
|
3
|
3
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
1
|
3
|
3
|
3
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
9
+4 250%
|
17
+95%
|
134
+689%
|
111
-17%
|
93
-17%
|
36
-61%
|
15
-60%
|
31
+113%
|
67
+117%
|
77
+15%
|
59
-23%
|
45
-24%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
3
|
1
|
2
|
3
|
4
|
4
|
0
|
1
|
1
|
1
|
1
|
7
|
2
|
|
| Accrued Liabilities |
1
|
1
|
2
|
4
|
3
|
5
|
0
|
1
|
2
|
2
|
9
|
2
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
2
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
4
|
13
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
6
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
4
|
2
|
4
|
9
|
7
|
13
|
6
|
3
|
3
|
4
|
10
|
14
|
17
|
|
| Long-Term Debt |
0
|
0
|
3
|
3
|
15
|
17
|
0
|
0
|
0
|
0
|
23
|
20
|
9
|
|
| Other Liabilities |
0
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
4
N/A
|
3
-3%
|
8
+138%
|
12
+43%
|
22
+86%
|
30
+40%
|
6
-79%
|
3
-56%
|
4
+36%
|
4
+5%
|
33
+725%
|
33
+1%
|
26
-21%
|
|
| Equity | ||||||||||||||
| Common Stock |
4
|
21
|
37
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
8
|
16
|
30
|
62
|
101
|
152
|
193
|
29
|
44
|
61
|
102
|
145
|
182
|
|
| Additional Paid In Capital |
0
|
1
|
2
|
185
|
190
|
214
|
223
|
41
|
71
|
124
|
146
|
171
|
201
|
|
| Total Equity |
3
N/A
|
5
N/A
|
9
+70%
|
123
+1 261%
|
89
-27%
|
62
-30%
|
30
-52%
|
12
-61%
|
27
+132%
|
63
+133%
|
44
-30%
|
26
-41%
|
19
-27%
|
|
| Total Liabilities & Equity |
0
N/A
|
9
+4 250%
|
17
+95%
|
134
+689%
|
111
-17%
|
93
-17%
|
36
-61%
|
15
-60%
|
31
+113%
|
67
+117%
|
77
+15%
|
59
-23%
|
45
-24%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
2
|
2
|
5
|
22
|
28
|
30
|
33
|
38
|
|